By Vandana Singh Apellis Pharmaceuticals Inc (NASDAQ: APLS) reported a second quarter (Q2) EPS loss of $1.02, beating the consensus of -$1.35. Apellis Pharmaceuticals Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its second quarter 2023 financial results and business highlights. “We made important progress in the second quarter, highlighted by strong commercial execution of the SYFOVRE […]
The post Apellis Pharmaceuticals Reports Q2 Earnings Beat, Investigates Retinal Vasculitis Events first appeared on The Florida Star | The Georgia Star.
